Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 38

1.

Interpretive categorical accuracy of fluoroquinolone reference broth microdilution MIC results when testing Streptococcus pneumoniae: selection of a surrogate testing agent.

Sader HS, Koeth LM, Poupard JA, Jones RN.

Diagn Microbiol Infect Dis. 2008 Dec;62(4):460-3. doi: 10.1016/j.diagmicrobio.2008.08.020. Epub 2008 Nov 5.

PMID:
18990533
2.

Temporal and spatial distribution of clonal complexes of Streptococcus pneumoniae isolates resistant to multiple classes of antibiotics in Belgium, 1997 to 2004.

Amrine-Madsen H, Van Eldere J, Mera RM, Miller LA, Poupard JA, Thomas ES, Halsey WS, Becker JA, O'Hara FP.

Antimicrob Agents Chemother. 2008 Sep;52(9):3216-20. doi: 10.1128/AAC.00358-08. Epub 2008 Jun 23.

3.
4.

Molecular evolution perspectives on intraspecific lateral DNA transfer of topoisomerase and gyrase loci in Streptococcus pneumoniae, with implications for fluoroquinolone resistance development and spread.

Stanhope MJ, Walsh SL, Becker JA, Italia MJ, Ingraham KA, Gwynn MN, Mathie T, Poupard JA, Miller LA, Brown JR, Amrine-Madsen H.

Antimicrob Agents Chemother. 2005 Oct;49(10):4315-26.

5.

In vitro activity of gemifloxacin and contemporary oral antimicrobial agents against 27247 Gram-positive and Gram-negative aerobic isolates: a global surveillance study.

Bouchillon SK, Hoban DJ, Johnson JL, Johnson BM, Butler DL, Saunders KA, Miller LA, Poupard JA.

Int J Antimicrob Agents. 2004 Feb;23(2):181-96.

PMID:
15013045
6.

A review of the antimicrobial activity of clavulanate.

Finlay J, Miller L, Poupard JA.

J Antimicrob Chemother. 2003 Jul;52(1):18-23. Epub 2003 May 29. Review.

PMID:
12775671
7.

Comparative in vitro potency of amoxycillin-clavulanic acid and four oral agents against recent North American clinical isolates from a global surveillance study.

Hoban DJ, Bouchillon SK, Johnson JL, Zhanel GG, Butler DL, Saunders KA, Miller LA, Poupard JA; Surveillance Study Research Group.

Int J Antimicrob Agents. 2003 May;21(5):425-33.

PMID:
12727075
8.

Comparative in vitro surveillance of amoxicillin-clavulanic acid and four oral comparators against 21232 clinical isolates from europe.

Hoban DJ, Bouchillon SK, Johnson JL, Zhanel GG, Butler DL, Saunders KA, Miller LA, Poupard JA.

Eur J Clin Microbiol Infect Dis. 2003 Apr;22(4):261-7. Epub 2003 Mar 28.

PMID:
12709842
9.

The growth and survivability of Streptococcus pneumoniae clinical isolates subjected to various environmental conditions.

Mazzola GJ, Mortensen JE, Miller LA, Poupard JA.

Diagn Microbiol Infect Dis. 2003 Mar;45(3):153-64.

PMID:
12663156
10.

Comparative in vitro potency of gemifloxacin and fluoroquinolones against recent European clinical isolates from a global surveillance study.

Hoban DJ, Bouchillon SK, Johnson JL, Zhanel GG, Butler DL, Miller LA, Poupard JA; Gemifloxacin Surveillance Study Research Group.

Eur J Clin Microbiol Infect Dis. 2001 Nov;20(11):814-9.

PMID:
11783700
11.

Comparative in vitro activity of gemifloxacin, ciprofloxacin, levofloxacin and ofloxacin in a North American surveillance study.

Hoban DJ, Bouchillon SK, Johnson JL, Zhanel GG, Butler DL, Miller LA, Poupard JA; Gemifloxacin Surveillance Study Research Group.

Diagn Microbiol Infect Dis. 2001 May-Jun;40(1-2):51-7.

PMID:
11448564
12.
13.

Comparison of cation-adjusted Mueller-Hinton broth with Iso-Sensitest broth for the NCCLS broth microdilution method.

Koeth LM, King A, Knight H, May J, Miller LA, Phillips I, Poupard JA.

J Antimicrob Chemother. 2000 Sep;46(3):369-76.

PMID:
10980162
14.

Differences between the activity of penicillin, amoxycillin, and co-amoxyclav against 5,252 Streptococcus pneumoniae isolates tested in the Alexander Project 1992-1996.

Butler DL, Gagnon RC, Miller LA, Poupard JA, Felmingham D, Gr√ľneberg RN.

J Antimicrob Chemother. 1999 Jun;43(6):777-82.

PMID:
10404316
15.

Escherichia coli ATCC 35218 as a quality control isolate for susceptibility testing of Haemophilus influenzae with haemophilus test medium.

Butler DL, Jakielaszek CJ, Miller LA, Poupard JA.

Antimicrob Agents Chemother. 1999 Feb;43(2):283-6.

16.

A 5-year surveillance study of 44,691 isolates of Haemophilus influenzae project Beta-Alert 1993-1997.

Derecola A, Butler DL, Kaplan RL, Miller LA, Poupard JA.

Antimicrob Agents Chemother. 1999 Jan;43(1):185-6.

17.

Comparison of the 5 microg disc and the Neo-Sensitab for determining the susceptibilities of Staphylococcus aureus isolates to mupirocin.

Finlay JE, Miller LA, Poupard JA.

J Antimicrob Chemother. 1998 Sep;42(3):403-5. No abstract available.

PMID:
9786487
18.

Interpretive criteria for testing susceptibility of staphylococci to mupirocin.

Finlay JE, Miller LA, Poupard JA.

Antimicrob Agents Chemother. 1997 May;41(5):1137-9.

20.

Stability of amoxicillin-clavulanate in BACTEC medium determined by high-performance liquid chromatography and bioassay.

Moore TD, Horton R, Utrup LJ, Miller LA, Poupard JA.

J Clin Microbiol. 1996 May;34(5):1321-2.

21.

Update on mupirocin resistance.

Poupard JA.

J Chemother. 1995 Jul;7 Suppl 3:71-4. Review.

PMID:
8609541
22.
23.

A survey of beta-lactamase-producing Haemophilus influenzae. An evaluation of 5750 isolates.

Rittenhouse SF, Miller LA, Kaplan RL, Mosely GH, Poupard JA.

Diagn Microbiol Infect Dis. 1995 Apr;21(4):223-5.

PMID:
7554806
24.

Comparison of mupirocin susceptibility of nasal and nonnasal Staphylococcus aureus isolates.

Utrup LJ, Finlay JE, Rittenhouse SF, Poupard JA.

Diagn Microbiol Infect Dis. 1994 Nov;20(3):171-4.

PMID:
7874886
25.

Comparison of three methods for determination of a single MIC of an antimicrobial agent.

Miller LA, Rittenhouse SF, Utrup LJ, Poupard JA.

J Clin Microbiol. 1994 May;32(5):1373-5.

26.

The evolution of antimicrobial susceptibility testing methods.

Poupard JA, Rittenhouse SF, Walsh LR.

Adv Exp Med Biol. 1994;349:3-14. No abstract available.

PMID:
8209807
27.

Correlation of minimum inhibitory concentration results between the Vitek system and the BIOMIC system.

Wolfram TL, McFarland CR, Poupard JA.

Adv Exp Med Biol. 1994;349:177-86. No abstract available.

PMID:
8209805
28.

Current issues in antimicrobial susceptibility testing.

Poupard JA, Walsh LR.

Adv Exp Med Biol. 1994;349:153-6. No abstract available.

PMID:
8209802
29.

History of biological warfare: catapults to capsomeres.

Poupard JA, Miller LA.

Ann N Y Acad Sci. 1992 Dec 31;666:9-20. No abstract available.

PMID:
1297284
30.

Ticarcillin-clavulanic acid zone size criteria.

Poupard JA, Wester B.

Antimicrob Agents Chemother. 1992 Oct;36(10):2352. No abstract available.

31.

Tropical neuromyelopathies and retroviruses: a review.

Bucher B, Poupard JA, Vernant JC, DeFreitas EC.

Rev Infect Dis. 1990 Sep-Oct;12(5):890-9. Review.

PMID:
2173097
32.

Lydia Rabinowitsch, PhD, and the emergence of clinical pathology in late 19th-century America.

Walsh LR, Poupard JA.

Arch Pathol Lab Med. 1989 Nov;113(11):1303-8. No abstract available.

PMID:
2684093
33.
34.

Lack of transmission of hepatitis non-A, non-B by CPR manikins.

Perras ST, Poupard JA, Byrne EB, Nast PR.

N Engl J Med. 1980 Jan 10;302(2):118-9. No abstract available.

PMID:
6765980
35.

Biology of the bifidobacteria.

Poupard JA, Husain I, Norris RF.

Bacteriol Rev. 1973 Jun;37(2):136-65. Review. No abstract available.

36.

Influence of nutrition on the morphology of a strain of Bifidobacterium bifidum.

Husain I, Poupard JA, Norris RF.

J Bacteriol. 1972 Sep;111(3):841-4.

37.

Effect of storage of Mueller-Hinton agar plates on zone sizes for antimicrobial testing.

Dewees LB, Poupard JA, Morton HE.

Appl Microbiol. 1970 Sep;20(3):293-7.

38.

Antibiotic susceptibility of Klebsiella-Enterobacter as determined by a single high-concentration disc method.

Poupard JA, Dewees LB, Morton HE.

Antimicrob Agents Chemother (Bethesda). 1969;9:489-94. No abstract available.

PMID:
5396527

Supplemental Content

Loading ...
Support Center